Torrent Pharmaceuticals Ltd - 500420 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of Loss of Share Certificate11-12-2019
Torrent Pharmaceuticals Ltd - 500420 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of Loss of Share CertificateTorrent Pharmaceuticals Ltd - 500420 - Name Change Of Of Registrar & Share Transfer Agent From 'KARVY FINTECH PRIVATE LIMITED' To 'KFIN TECHNOLOGIES PRIVATE LIMITED'
The Company has been informed that the name of Registrar & Share Transfer Agent (RTA) has been changed from KARVY FINTECH PRIVATE LIMITED to KFIN TECHNOLOGIES PRIVATE LIMITED with effect from 05th December, 2019. We request you to take note of the same and update the name of 'KFIN TECHNOLOGIES PRIVATE LIMITED' as the RTA of the Company in your records.Torrent Pharmaceuticals Ltd - 500420 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Advertisement In Respect Of transfer of shares to IEPFTorrent Pharmaceuticals Ltd - 500420 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of Issue of Duplicate Share CertificateUSFDA red flags Torrent Pharma's US-based plant for manufacturing violations
The American health regulator has pulled up Torrent Pharmaceuticals' US-based subsidiary for violations of good manufacturing practices, including aTorrent Pharmaceuticals Ltd - 500420 - Compliance As Per Regulation 23(9) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Pursuant to regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, kindly find enclosed the Related Party Transactions on a consolidated basis for the half year ended on 30-Sep-19. Kindly take note of the above.Torrent Pharmaceuticals Ltd - 500420 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of Loss of Share CertificateTorrent Pharma in a medium-term uptrend
The stock breached 50- and 200-day moving averages; key resistance now at 1,850Torrent Pharma: Domestic market, a revenue booster
Healthy growth was aided by higher sales, price hikes and new product launches